Seattle Genetics reports updated Adcetris plus Opdivo Hodgkin lymphoma data
Seattle Genetics announced updated and long-term follow-up analyses from two clinical trials evaluating Adcetris and Opdivo in frontline Hodgkin lymphoma patients aged 60 years and older and in relapsed or refractory classical HL. Results were presented today at the American Society of Hematology Annual Meeting. Data were reported from 21 patients, and the median age was 72 years. Of 19 response-evaluable patients, 18 patients had an objective response, including 13 patients with a complete response and five patients with a partial response. All response-evaluable patients experienced tumor reduction following treatment with Adcetris in combination with Opdivo. Median duration of response was not yet reached and the maximum duration of response was 22 months and ongoing, the company added. The most common treatment-related adverse events of any grade occurring in at least 20% of patients were fatigue, diarrhea, pyrexia, infusion related reaction, peripheral motor neuropathy, peripheral sensory neuropathy and increase in lipase.Data were reported from 93 patients with relapsed or refractory classical HL after failure of frontline therapy who received the combination regimen of Adcetris plus Opdivo. Of the 91 treated patients, 85 percent had an objective response, including 67% with a complete response, 16 patients with a partial response and six patients had stable disease. Of the 91 treated patients, 67 patients received an ASCT per trial protocol with no additional salvage therapy.